Triple
T4784989
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | mAb114 |
E106453
|
entity |
| Predicate | sponsor |
P67
|
FINISHED |
| Object |
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
|
E468969
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69bd43f4a9588190bf73e20bc27c03cc |
elicitation | completed |
| NER | batch_69bd65ae49ec81908f16248d22d1155f |
ner | completed |
| NED1 | batch_69be43dbdec88190817845e7930a18f6 |
ned_source_triple | completed |
| NED2 | batch_69be45f5ebec8190b62c428b465d1bd9 |
ned_description | completed |
| NEDg | batch_69be447c21d48190ab57c8761e733ff4 |
nedg | completed |
Created at: March 20, 2026, 1:22 p.m.